PCI-32765
Showing 1 - 25 of 1,765
Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)
Active, not recruiting
- Waldenstrom Macroglobulinemia
-
Changchun, China
- +5 more
Jan 27, 2023
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)
Recruiting
- Breast Neoplasms
- Malignant Neoplasm of Breast
- Trastuzumab
- +3 more
-
Dallas, Texas10 sites incl TX, WA, VA, and NV
May 16, 2022
CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)
Recruiting
- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- +2 more
- Ibrutinib
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia) Trial run by the NHLBI (PCI 32765)
Active, not recruiting
- Leukemia
- +3 more
- PCI 32765
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 2, 2021
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)
Active, not recruiting
- Waldenstrom Macroglobulinemia
-
Chiba, Japan
- +8 more
Jan 27, 2023
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in
Recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +5 more
- Ibrutinib
- +2 more
-
Fresno, California
- +2 more
Jan 24, 2023
Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)
Recruiting
- Chronic Lymphocytic Leukemia
- Daratumumab
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 24, 2022
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Stage I Chronic Lymphocytic Leukemia
- +3 more
- Ibrutinib
- Laboratory Biomarker Analysis
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 24, 2022
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in United States (Ibrutinib,
Active, not recruiting
- Metastatic Melanoma
- +2 more
- Ibrutinib
- +3 more
-
Los Angeles, California
- +12 more
Jul 27, 2022
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Tumor, Chronic Lymphocytic Leukemia Trial in Rochester (Ibrutinib,
Withdrawn
- Asymptomatic COVID-19 Infection Laboratory-Confirmed
- +8 more
- Ibrutinib
- Quality-of-Life Assessment
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 2, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +4 more
- Daratumumab
- Ibrutinib
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in
Active, not recruiting
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 20, 2023
Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Completed
- Loss of Chromosome 17p
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 4, 2022
Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)
Completed
- Waldenstrom's Macroglobulinemia
-
Boston, Massachusetts
- +1 more
Dec 5, 2022
Aplastic Anemia, Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial in Columbus (Best Practice, Ibrutinib)
Active, not recruiting
- Aplastic Anemia
- +6 more
- Best Practice
- Ibrutinib
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 24, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Chronic Lymphocytic Leukemia, Loss of Chromosome 17p Trial (Ibrutinib, Venetoclax)
Withdrawn
- Chronic Lymphocytic Leukemia
- Loss of Chromosome 17p
- (no location specified)
Oct 29, 2021
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Active, not recruiting
- Prolymphocytic Leukemia
- +2 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)
Completed
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Ibrutinib
- Obinutuzumab
-
Portland, OregonOHSU Knight Cancer Institute
Dec 10, 2021